Joanne M. Donovan net worth and biography

Joanne Donovan Biography and Net Worth

Joanne M. Donovan, M.D., Ph.D., has served as our Chief Medical Officer since 2021. Most recently, Dr. Donovan served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals. Since 1989, she has been a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex Pharmaceuticals. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.

What is Joanne M. Donovan's net worth?: The estimated net worth of Joanne M. Donovan is at least $494,292.00 as of September 20th, 2024. Dr. Donovan owns 14,538 shares of Edgewise Therapeutics stock worth more than $494,292 as of November 2nd. This net worth evaluation does not reflect any other assets that Dr. Donovan may own. Additionally, Dr. Donovan receives a salary of $696,400.00 as CMO at Edgewise Therapeutics. Learn More about Joanne M. Donovan's net worth.
How old is Joanne M. Donovan?: Dr. Donovan is currently 67 years old. There are 7 older executives and no younger executives at Edgewise Therapeutics. Learn More on Joanne M. Donovan's age.
What is Joanne M. Donovan's salary?: As the CMO of Edgewise Therapeutics, Inc., Dr. Donovan earns $696,400.00 per year. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on Joanne M. Donovan's salary.
How do I contact Joanne M. Donovan?: The corporate mailing address for Dr. Donovan and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Joanne M. Donovan's contact information.
Has Joanne M. Donovan been buying or selling shares of Edgewise Therapeutics?: Joanne M. Donovan has not been actively trading shares of Edgewise Therapeutics within the last three months. Most recently, Joanne M. Donovan sold 7,162 shares of the business's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $28.29, for a transaction totalling $202,612.98. Following the completion of the sale, the chief marketing officer now directly owns 14,538 shares of the company's stock, valued at $411,280.02. Learn More on Joanne M. Donovan's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

Joanne M. Donovan Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/20/2024	Sell	7,162	$28.29	$202,612.98	14,538
5/2/2024	Sell	3,682	$18.91	$69,626.62	19,897
5/2/2023	Sell	3,254	$8.90	$28,960.60	9,960

Joanne M. Donovan Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $34.00

$33.48

$34.12

50 Day Range

MA: $26.29

$16.85

$35.57

2 Week Range

Now: $34.00

$5.12

$36.66

Volume

445,358 shs

Average Volume

958,294 shs

Market Capitalization

$3.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

This is treason

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Joanne Donovan Biography and Net Worth

What is Joanne M. Donovan's net worth?

How old is Joanne M. Donovan?

What is Joanne M. Donovan's salary?

How do I contact Joanne M. Donovan?

Has Joanne M. Donovan been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?